Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Adverse drug events during AKI and its recovery.

Cox ZL, McCoy AB, Matheny ME, Bhave G, Peterson NB, Siew ED, Lewis J, Danciu I, Bian A, Shintani A, Ikizler TA, Neal EB, Peterson JF.

Clin J Am Soc Nephrol. 2013 Jul;8(7):1070-8. doi: 10.2215/CJN.11921112. Epub 2013 Mar 28.

2.

Medication-Induced Nephrotoxicity in Older Patients.

Fusco S, Garasto S, Corsonello A, Vena S, Mari V, Gareri P, Ruotolo G, Luciani F, Roncone A, Maggio M, Lattanzio F.

Curr Drug Metab. 2016;17(6):608-25. Review.

PMID:
27048182
3.

Transporters affecting biochemical test results: Creatinine-drug interactions.

Chu X, Bleasby K, Chan GH, Nunes I, Evers R.

Clin Pharmacol Ther. 2016 Nov;100(5):437-440. doi: 10.1002/cpt.445. Epub 2016 Sep 15. Review.

PMID:
27509262
4.

Molecular determinants of acute kidney injury.

Husi H, Human C.

J Inj Violence Res. 2015 Jul;7(2):75-86. doi: 10.5249/jivr.v7i2.615. Review.

5.

Nephrotoxicities.

Goldstein SL.

F1000Res. 2017 Jan 19;6:55. doi: 10.12688/f1000research.10192.1. eCollection 2017. Review.

6.

Emergence of biomarkers in nephropharmacology.

Khan E, Batuman V, Lertora JJ.

Biomark Med. 2010 Dec;4(6):805-14. doi: 10.2217/bmm.10.115. Review.

7.

Mechanistic biomarkers for cytotoxic acute kidney injury.

Vaidya VS, Bonventre JV.

Expert Opin Drug Metab Toxicol. 2006 Oct;2(5):697-713. Review.

PMID:
17014390
8.

Optimising the use of medicines to reduce acute kidney injury in children and babies.

Oni L, Hawcutt DB, Turner MA, Beresford MW, McWilliam S, Barton C, Park BK, Murray P, Wilm B, Copple I, Floyd R, Peak M, Sharma A, Antoine DJ.

Pharmacol Ther. 2017 Jun;174:55-62. doi: 10.1016/j.pharmthera.2017.02.018. Epub 2017 Feb 12. Review.

PMID:
28202365

Supplemental Content

Support Center